anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means usable in cleanly healing a wound so as not to leave an excoriation.  &lt;P&gt;SOLUTION: A mesenchymal cell is derived from a mammal and has a wound healing ability. The mesenchymal cell is obtained from mammalian bone marrow, menstrual blood or umbilical cord blood and has the wound healing ability. The mammal can be a rat, a pig or a human. A method for preparing the mesenchymal cell having the wound healing ability for transplantation into the wound of a patient comprises isolating the mesenchymal cell having the wound healing ability from the bone marrow, menstrual blood or umbilical cord blood of the patient having the wound and culturing the isolated cell. A method for treating the wound comprises transplanting an effective amount of the mesenchymal cell having the wound healing ability to the wound of the patient. A wound treating agent comprises the mesenchymal cell having the wound healing ability as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
FIELD: medicine, otorhinolaryngology, disinfection. SUBSTANCE: copper derivatives of chlorophyll from laminaria lipid complex are used as an active substance. Water-alcohol solutions and solutions in vegetable oil, nutritive supplement named &#34;Phytolon&#34; are used at concentration of 0.003-0.05% active substance. Treatment is conducted by irrigation, dropping in, rinsing for 3-7 days as dependent on disease. EFFECT: higher efficiency of therapy which along disinfecting and antiinflammatory action activates immunostimulating properties. 7 cl, 1 tbl
The invention provides a traditional Chinese medicine for treating lameness of equine animals, which comprises the following components in percentage by weight: 50 g of leech (stir-fried until the yellow smoke is the same degree, singly Bao Yan powder), 40 g of frankincense, 40 g of myrrh, 50 g of dragon&#39;s blood (singly Bao Yan powder), 30 g of fructus forsythiae, 30 g of Chinese angelica, 30 g of szechuan lovage rhizome, 20 g of raw nutgrass galingale rhizome, 20 g of costus root and 30 g of dried orange peel. The application method is that about 700-750 milliliters (of child feces) is taken as a guide, decocted with water and infused with water at a temperature. The medicine can be used for curing after every other day, and the medicine can be used for curing after 3-5 doses. The first diagnosis can be combined with acupuncture, the lameness of the front limbs can be put on chest cavity, the curvature of the rear limbs can be that of the acupuncture and moxibustion, the big crotch, the small crotch and the intersection. Bleeding is preferably carried out by 50-300 ml. The preparation has the effects of detumescence, removing blood stasis, relieving pain and healing. The curative effect is better according to different symptoms in clinic. The preparation is taken orally after fracture and dislocation are matched with bone setting operation, so that the curative effect is improved, and livestock is healed early, thereby reducing economic loss.
PURPOSE: To provide water-contg. gel having excellent stability and whose gelation strength is not lowered with time by decomposition, by a method wherein a mixt. of water, a specified reaction product and at least one gelatinizer selected from polyamines is subjected to gelation treatment.  
     CONSTITUTION: (B) 0.1W20wt% of at least one gelatinizer selected from polyamines of formula (wherein n is 1W50) is mixed with (A) an aq soln. of 10W 60wt% of a reaction product obtd. by reacting ammonia in an amount of 0.5W2mol per mole of maleic anhydride gp. in a copolymer with the copolymer obtd. by copolymerizing one mole of maleic anhydride with 1W3 moles of at least one monomer selected from α-olefin such as ethylene, propylene and vinyl cpd. such as styrene, vinyl acetate in order to obtain uniform aq. soln. The aq. soln is casted into the desired mold and gelled under a room temp. or heating. By this procedure, there is obtained water-contg. gel which is stable to alkali, acid, freezing and high temp. or repeated cycle of freezing-high temp. 
     COPYRIGHT: (C)1980,JPO&amp;Japio
The term “medical cannabis” and “medical marijuana” existed long before any codifying of law. They were around before industry began and the words actually had meaning. Medical cannabis means sensimilla, and sensimilla is a latin word meaning “without seed.” The reason sensimilla is preferred for medicine is simple. Cannabis plants are highly photo-sensitive. This means the plant&#39;s entire life cycle must be controlled with light to efficiently and effectively produce medicine. When done properly you will have a vegetative photo-period and a flower photo-period, each being different in duration, intensity, and color of lighting. Working like this allows you to keep a “mother plant” theoretically indefinitely. This allows you to increase plant potency over time and gives you a source for clones. Clones can be developed directly beside the mother until ready to flower. Establishing a mother plant and taking clones allows for a few things. First, you now have a reliable source of female cannabis plants and no seeds are required to be germinated. Second, potency goes up the longer the mother is in the vegetative state. Third, if there are any abnormalities it is easy to spot. Training yourself to cultivate in this manner will make it really easy to identify when “somethings wrong”, and with cannabis something wrong can turn catastrophic quickly. When the female clone has matured and is ready for flowering they are moved away from the mother. They are provided with a different color of light, as well as duration of light and nutrients. When a cannabis plant is flowering in this manner and no male plants are present, and no pollination occurs, it is now in prime condition to provide our medicine, in the form of its resin. In nature, the resin is what the plant uses to entice pollination. If unpollinated, a cannabis plant will freely flow its resin until harvest. If pollinated, it begins to shut down resin flow because it no longer needs to be pollinated. This is when the plant begins to put its energy into seed production and inhibits our medicine. It is particularly this reason why it is imperative for “medical cannabis” to meet the standard of sensimilla.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent having excellent antiallergic action with slight side effects, and useful as e.g. a medicament for preventing or treating diseases caused by various kinds of allergy by including a specific naphthoquinone derivative. SOLUTION: This allergic disease therapeutic agent contains a naphthoquinone derivative of formula I, II or III [2,2-&#34;-methylenebis(3- hydroxy-1,4-naphthoquinone), 2,2&#39;-ethylidenebis(3-hydroxy-1,4-naphthoquinone), 2-hydroxyethyl)-3-methoxy-1,4-naphthoquinone, respectively]. Each of these naphthoquinone derivatives can be extracted and isolated from lmpatience balsamina L.; it is obtained, for example, by cutting the whole grass, leaves, stems, rinds, or petals of the above plant with or without drying and subjecting them to extraction at normal or higher temperatures with a solvent (e.g. water, an organic solvent, a mixture thereof), or by synthesis. The daily dose of this agent is normally 0.1-500 or 0.01-100 mg/adult for external use or internal use, respectively.
S-Carboxymethylcysteine &lt;FORM:1071807/C2/1&gt; is prepared by alkylating cysteine with an alkali metal monochloroacetate, in the presence of a proton acceptor, preferably NaOH the reaction is carried out in aqueous solution at about 5 DEG C., under inert gas (nitrogen) and when complete the product is precipitated by acidifying the reaction mixture and recrystallized from alkaline solution by addition of acid. The product is afterwards converted to its sodium salt in aqueous solution, for use in a pharmaceutical composition (see Divisions A5-A6).ALSO:Pharmaceutical compositions for topical application comprise a water-in-oil emulsion of a solution of a non-toxic, water-soluble salt of S-carboxymethyl cysteine in an aqueous phase uniformly dispersed throughout a non-toxic topically applicable unguent lipid carrier as the non-aqueous phase. The composition preferably includes one or more surface active agents, such as polyoxyethylene sorbitan monooleate, alkali metal lauryl sulphonates, and triethanolamine stearate. The preferred soluble salts are those of alkali metals or ammonium organic bases such as mono-or tri-ethanolamine, or basic aminoacids such as lysine or arginine. The lipid medium may contain one or more of glyceryl mono-stearate or-palmitate, lanolin or hydrogenated lanolin, perhydrosqualene, polyethylene glycols, propylene glycol stearate, hydrogenated oils and mixed esters of glycerol and polyoxyethylene glycol obtained by subjecting oils such as almond p oil to alcoholysis in the presence of polyoxyethylene glycols, cholesterol or its palmitate, sorbital, preservatives, (benzalkonium chloride or sorbic acid), and suitable coloring agents. Other active ingredients may be present, such as thyroxin and vitamin A. The compositions are useful for treating fragility of human nails.
BACKGROUND AND PURPOSE: <p>To determine the risk of hemorrhagic transformation in patients with acute ischemic cerebrovascular disease, we investigated the relationship between Apparent Diffusion Coefficient Magnetic Resonance Imaging values measured within the infarct area and microbleeds observed on Gradient Echo Sequence Magnetic Resonance Imaging.</p>.
METHODS: <p>A total of 172 patients who were hospitalized to the Neurology Clinic of the Istanbul Provincial Directorate of Health Erenkoy Mental and Nervous Diseases Training and Research Hospital between June 2019 and March 2020 were included in this cross-sectional study. The patients were classified according to their demographic and clinical characteristics, by age, gender, hypertension, diabetes mellitus, smoking, and alcohol use. In the Cranial Magnetic Resonance Imaging taken in the application for the diagnosis of acute ischemic cerebrovascular disease, the infarction area in Apparent Diffusion Coefficient sequences with the Region of Interest value and the relationship between microhemorrhage observed in Gradient Echo hemo-sequence was evaluated in Magnetic Resonance Imaging applied between 3-7 days. While calculating spherical Region of Interest values, 5 Region of Interest values were obtained for lesions larger than 1.5x1.5 cm, and their arithmetic mean was obtained, and single spherical Region of Interest value was taken for smaller ones. Apparent Diffusion Coefficient Magnetic Resonance Imaging Region of Interest mean values were divided into 2 groups as &lt;500x10&ndash;6 mm2 /s and &gt;500x10&ndash;6 mm2/s.&nbsp;</p>.
RESULTS: <p>Patients in the group with Apparent Diffusion Coefficient Region of Interest mean values below 500x10-6 mm2/s, had a significantly higher probability for microhemorrhage observes in Gradient Echo Sequence Magnetic Resonance Imaging (p: 0.001) and also more likely to experience microhemorrhage in other areas, which was statistically significant (p: 0.001).The probability of another micro-bleeding observed in patients with microhemorrhage Gradient Echo Sequence Magnetic Resonance Imaging was also statistically significant (p: 0,001). The risk of microbleeding in areas other than ischemia was also found to be significantly higher in patients with microbleeding in the ischemia area in Gradient Echo Sequence Magnetic Resonance Imaging.</p>.
CONCLUSION: <p>In our study, a statistically significant relationship was found between the microhemorrhage in the infarct area and the Apparent Diffusion Coefficient Region of Interest values. When the literature was reviewed, no such study was found to determine the risk of bleeding.</p>.
A medical history documentation system and method for recording information relating to at least one of a designated patient&#39;s current medical condition, a physical examination, a diagnosis and a treatment plan is shown. The system includes a recording member having a plurality of discrete recording sections formed thereon programmed for recording information relating to the patient. The encoded indicia is communicated by a first person to a second person during a physical examination of the patient by the first person. An input member is used by the second person for recording medical information in the form of predetermined encoded indicia in applicable discrete recording sections of the recording member. A transcriber having a plurality of report section templates is used. Each report section template corresponds to a discrete recording section. Each of the report section templates comprise a plurality of optional text variable segments each of which are assigned to a selected one of the predetermined encoded indicia. The transcriber is operative to decode each one of the predetermined encoded indicia recorded on the recording member. An imaging device responsive to the transcriber prepares a patient&#39;s report specific to the designated patient. A method for using the system is shown.
&lt;P&gt;PROBLEM TO BE SOLVED: To extract and purify a carbonic anhydrase VI from milk or whey which is obtained in a large amount and has an eating experience in human.  &lt;P&gt;SOLUTION: The active type carbonic anhydrase VI is isolated from whey or milk. The method for producing an active type carbonic anhydrase VI comprises a process for treating whey or milk with an acid. The composition for the oral cavity comprises the active type carbonic anhydrase VI. Having buffering ability of saliva, the composition for the oral cavity is expected to have inhibitory effect on progress of dental caries, ameliorating effect on dysgeusia and to prevent outbreak of gastritis from neutralization effect on gastric acid.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hairdye composition which hardly shows color loss caused by washing the hair after dyeing, a method of dyeing the hair using the hairdye and a method of preventing color loss from the dyed hair.  &lt;P&gt;SOLUTION: The hairdye includes components (A)-(C) below. The method of dyeing the hair includes applying the hairdye to the hair, letting it stand for 1-60 minutes, and washing it away. The method of preventing color loss from the dyed hair includes applying a composition containing the component (A) to the hair during the hairdyeing or after the hairdyeing. (A) Astaxanthine or its derivatives. (B) An oxidizer. (C) An alkaline agent.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;amp;INPIT
The invention comprises compounds of the formula &lt;FORM:0910428/IV (b)/1&gt; and their acid addition salts, in which A stands for a 1-5 membered hydrocarbon chain which may also contain a double bond or be interrupted by a nitrogen atom which may be unsubstituted or substituted by an alkyl or aralkyl group, m represents any one of the numbers from 0 to 6, m1 any one of the numbers from 0 to 3, R and R1 stand for hydrogen or C1-7 alkyl and Z for a primary or secondary amino group, with the proviso that CmH2m separates the bridgehead atoms by at most 2 carbon atoms, and in which &lt;FORM:0910428/IV (b)/2&gt; when A forms a 3-5-membered isocyclic ring with the bridge members and &lt;FORM:0910428/IV (b)/3&gt; when A forms a 4-membered azacyclic ring with the bridge members. The compounds may be prepared, for example, by reducing in compounds of the general formula: &lt;FORM:0910428/IV (b)/4&gt; in which A, m, n, n1, R and R1 have the meanings above and m1 stands for any one of the numbers 1-6, the cyano group to the methyleneamino group preferably by catalytic hydrogenation or with a di-light metal hydride or with aluminium hydride or aluminium borohydride if necessary in the presence of an activator such as aluminium chloride, or for example, by condensing a 1,2-cis-cycloaliphatic dicarboxylic acid anhydride with a lower alkylene diamine and reducing the resulting dioxo compound with a di-light metal hydride.  The aza-bicycloalkyl-(N)-alkyl cyanides are prepared by condensing the free base of the formula &lt;FORM:0910428/IV (b)/5&gt; with a reactive esterified cyano lower alkanol. b -Hexahydroindolino propionitrile is also prepared from hexahydroindoline and acrylonitrile.  Hexahydroindoline is prepared by reducing 4,7,8,9-tetrahydrophthalimide with lithium aluminium hydride to form 4,7,8,9-tetrahydroindoline which is hydrogenated. Decahydro-3-benzazepine is prepared by acetylating 2,3,4,5-tetrahydro - 3 - benzazepine, hydrogenating the 3-acetyl-2,3,4,5-tetrahydro-3-benzazepine to a mixture of the decahydro free base and 3-acetyl-decahydro-3-benzazepine and hydrolysing the acetyl compound.  N-methyl-bispidine is prepared by reacting bispidine with methyl formate to give N-formyl bispidine which is reduced with lithium aluminium hydride.
Synthetic agrimol B and derivatives thereof ( &#34;compounds&#34; ) that have anticancer properties are disclosed. Methods for synthesizing the compounds with an overall yield ≥ 7% are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating a cancer, reducing a cancer, or treating or ameliorating one or more symptoms associated with a cancer, such as non-small-cell lung cancer, in a subject are also disclosed. The methods include (i) administering to the subject the pharmaceutical formulation containing one or more compounds, for one or more times. The compounds can selectively kill cancer cells and/or cancer stem cells over non-cancerous cells by inducing mitochondria dysfunction and/or inhibiting ER to Golgi trafficking in the cancer cells and/or cancer stem cells.
&lt;P&gt;PROBLEM TO BE SOLVED: To extract an effective ingredient from a persimmon of an off-specification product that is discarded because of upgrading of liking or inferior appearances, a fully ripened product or a processing byproduct or the like, further a pericarp of a persimmon that is not eaten and mostly discarded, and to make effective use of the ingredient.  &lt;P&gt;SOLUTION: A shredded or ground fruit and/or pericarp of a persimmon is uniformly dispersed in an aqueous liquid where acetic acid is present and is subsequently subjected to solid-liquid separation to give solid matter and liquid matter. An alcohol is added to the resultant solid matter and liquid matter, which is then subjected to solid-liquid separation to give a functional composition comprising alcohol-solubles. Further, ethyl acetate is added to the alcohol-solubles to remove ingredients insoluble in ethyl acetate. Use of a persimmon having been irradiated with far-infrared radiation gives a composition excellent in functionality that can be utilized as a raw material of a pharmaceutical or a health food. Thus, new applications of a persimmon, particularly one that has been discarded, are established.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain an emulsified cosmetic stable in the emulsion system over a long period and high in safety, especially even when the cosmetic is a higher fatty acid salt emulsion type cosmetic containing an electrolytic salt, by compounding a specific nonionic surfactant. SOLUTION: This emulsified cosmetic contains the combination of (A) a higher fatty acid, (B) a nonionic surfactant having a HLB of &gt;=10, and (C) an electrolytic salt. The component A is preferably palmitic acid, stearic acid, oleic acid, isostearic acid, etc., and compounded in an amount of 0.5-5.0wt.%. The component B is preferably is a pluronic type compound such as a POE glycerol fatty acid ester or a POE fatty acid ester, a POE hardened caster oil derivative, etc., and compounded in an amount of 0.01-10wt.%. The component C is preferably magnesium chloride, citric acid, etc., and compounded in a concentration of 0.01-0.5mol.%. The cosmetic does not cause the change in the smell and the generation of lumps, and is an extremely excellent oil-in- water type emulsion type cosmetic.
Prepn. of an attenuated syncytial respiratory vaccine comprises senal passage of a virus in human diploid pulmonary fibroblasts at 30-38oC for a sufficient number of passages to attenuate its power, then recovering the virus A vaccine esp. contains frozen attenuated virus and a stabilizer, esp.  Sorbitol and gelatin.  This vaccine is used for prevention of respiratory disorders, esp. in children.  A typical vaccine was prepd. from a virus isolated from the throat subjected to two passages in monkey kidney cells then four passages in human diploid pulmonary fibroblast (WI-38).  The collected infected cell was grown in modified Eagle&#39;s medium.
A new cultivar of medicinal cannabis has been bred that renders large amounts of cannabidiolic acid (mg/gram ground flower weight)... greater than 10%. The cultivar moved from an outdoor to indoor environment produced similar levels of cannabidiolic (CBD) and similar cannabinoid profiles. Reproduced asexually, the same (greater than 10%) cannabidiolic acid amounts were rendered and this remains constant crop to crop.  THC levels do not change between 20 and 30% of that of the CBD-A  concentration.  High Pressure Liquid Chromatography (HPLC) determines Cannabinoid profiles where the amounts of the three most abundant cannabinoids (tetrahydrocannabinol, cannabinol and cannabidiol) and their acids are quantified. The cannabinoid profile relates directly to the physiological effects of the plant as a medicine. In addition, a genetic fingerprint of the strain has been generated using gel electrophoresis. Strains high in cannabidiolic acid are rare since commercial breeding has led to strains with large concentrations of tetrahydrocannabinol (THC) and very little cannabidiol making the strain in question rare. Hayley&#39;s Comet provides a unique cannabinoid profile containing large concentrations of CBD-A making it useful for medicaments for seizure disorder, pain and inflammation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an agent for prevention and treatment of gingival hypertrophy induced by adverse effects of a medicine such as a calcium antagonist, an antiepileptic agent, an immunosuppressant etc.  &lt;P&gt;SOLUTION: The new preventive and therapeutic agent for gingival hypertrophy comprises using Bupleurum root against gingival hypertrophy. A medicinal composition containing Bupleurum root is provided as the preventive and therapeutic agent for gingival hypertrophy. The toothpaste comprises Bupleurum root or the medicinal composition containing Bupleurum root as an effective means for preventing and treating gingival hypertrophy. Consequently, a patient of gingival hypertrophy suppresses and treats gingival hypertrophy only by using the toothpaste in the routine teeth brushing without changing an antiepileptic agent to a different kind of one.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT